Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (21-30 of 858) with videos related to

Pageof 86
Sort By:
Lancet (London, England)|April 3, 2009
Can the polypill save the world from heart disease?Christopher P Cannon
Journal of the American College of Cardiology|March 27, 2020
Low-Density Lipoprotein Cholesterol: Lower Is Totally BetterChristopher P Cannon
JAMA|April 19, 2002
Primary percutaneous coronary intervention for all?Christopher P Cannon
Lancet (London, England)|February 20, 2010
Balancing the benefits of statins versus a new risk-diabetesChristopher P Cannon
Clinical Cardiology|October 4, 2003
Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part IIChristopher P Cannon
Pharmacoeconomics|May 7, 2005
Cost-effectiveness of clopidogrelChristopher P Cannon
American Heart Journal|February 28, 2002
To cath or not to cath? That used to be the questionChristopher P Cannon
Clinical Cornerstone|May 3, 2008
Cardiovascular disease and modifiable cardiometabolic risk factorsChristopher P Cannon
The American Journal of Geriatric Cardiology|June 21, 2001
Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional TherapiesChristopher P. Cannon
Critical Pathways in Cardiology|March 15, 2008
Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapyChristopher P Cannon
Pageof 86

Showing results (21-30 of 858) with videos related to

Sort By:
Pageof 86
Lancet (London, England)|April 3, 2009
Can the polypill save the world from heart disease?Christopher P Cannon
Journal of the American College of Cardiology|March 27, 2020
Low-Density Lipoprotein Cholesterol: Lower Is Totally BetterChristopher P Cannon
JAMA|April 19, 2002
Primary percutaneous coronary intervention for all?Christopher P Cannon
Lancet (London, England)|February 20, 2010
Balancing the benefits of statins versus a new risk-diabetesChristopher P Cannon
Clinical Cardiology|October 4, 2003
Oral platelet glycoprotein IIb/IIIa receptor inhibitors--part IIChristopher P Cannon
Pharmacoeconomics|May 7, 2005
Cost-effectiveness of clopidogrelChristopher P Cannon
American Heart Journal|February 28, 2002
To cath or not to cath? That used to be the questionChristopher P Cannon
Clinical Cornerstone|May 3, 2008
Cardiovascular disease and modifiable cardiometabolic risk factorsChristopher P Cannon
The American Journal of Geriatric Cardiology|June 21, 2001
Elderly Patients with Acute Coronary Syndromes: Higher Risk and Greater Benefit from Antithrombotic and Interventional TherapiesChristopher P. Cannon
Critical Pathways in Cardiology|March 15, 2008
Risk stratification and the management of non-ST-segment elevation acute coronary syndromes: the role of antiplatelet therapyChristopher P Cannon
Pageof 86